Abiopharma

🔍 Torres Denice (Executive)

Company: Seaport Therapeutics, Inc. (SPTX)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Acquired 13,406 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: C | equity_swap_involved: false | shares_owned_after: 13,406.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 12,258 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-04-30 | Code: A | Expires: 2036-04-29 | equity_swap_involved: false | shares_owned_after: 12,258.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 13,406 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2

Footnotes:

• F1: Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-one basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering on May 4, 2026 without payment of further consideration. The Preferred Stock had no expiration date.
• F2: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
• F3: The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.